Member Info for draft

If not 77 today it will be on Monday morning

many got in that low, it moves quickly , most people around in current levels

There is no delisting

Just a takeover and bidding war

This will be in the weekend press

Looks like brh is next to omega on the risers list. Also developing a test kit

Joanna lumley's tweeting animal free research they partner with kirkstall

Coronavirus: Online applications for COVID-19 tests temporarily closed due to huge demand
Downing Street reveals that 5,000 home-testing kits were ordered within two minutes of the new website opening.
By Rob Powell, political correspondent, and Greg Heffer, political reporter

Friday 24 April 2020 13:55, UK

The online application system for essential workers to book coronavirus tests has temporarily closed following huge demand.

The new government website will reopen tomorrow following a large number of applications.

Within hours of the new website going live this morning, those looking to book a coronavirus test online were met with the message to "check back later", after being told: "You can't currently register for a COVID-19 test."
Earlier, the website had also displayed the message that Friday's allocation of home-testing kits had already been reached.

£1 , revise target to 100p. Tight shareholding structure

im revising my targets here - the nearest company with a plausible test is worth 30million

our mcap 5 mill

if Paraytec and Sentinel Medical announce a test with aptamer Group this will go skyhigh

could easily see 40p fast when the market takes notice - I still think BRH is under the radar

housebuilders are bouncing up hard

12.30pm: Urban Exposure gets bid approach
Urban Exposure PLC (LON:UEX) saw its shares harden 8.6% to 38p after it threw light on a proposal by Wellesley Group Investors.
The residential development finance provider has received several enquiries in respect of the potential sale of its loan book, one of which has led to a proposal by Wellesley to acquire Urban Exposure’s assets, including its management operations, on terms that Wellesley says value Urban Exposure at 76.9p per share.

Urban Exposure PLC (UEX)
Price Monitoring Extension

also involved with OBD and thats well down from one pound,. any covid news there and that could do 50% like Scancell did today

this is a no brainer - it could do a huge gap up on Monday morning after sunday press

2 Takeover offers, and a potential bidding war and no delist at all

The Wellesley proposal is to acquire the Company's assets, including its management operations, on terms which Wellesley equates to a value of 76.9 pence per ordinary share of the Company.

this moves up in a flash

it cant stop anywhere else.

Snooze you lose, the Friday gift

just looks daft this, bidding war coming

Current COVID-19 tests only tell you if the virus is in your body – not whether you are still infectious.
But Prof Lorna Harries and her team at our Animal Replacement Centre (ARC2.0) at the University of Exeter are currently optimising a test that could tell users not only whether they are carrying active virus, but also how much.
The current test for the COVID-19 virus includes ingredients derived from animals and detects only the presence of viral particles (which can be infectious or non-infectious). Lorna’s new test will be animal free as all animal-derived materials are replaced by synthetic equivalents.
By using human tissue samples from COVID-19 infected people, Lorna and her team are able to make their research truly human relevant and detect the exact number of copies of active viral particles in a sample. This test has three major benefits. It will:
Get healthcare workers back to work faster and safely
Help predict how poorly people are likely to become
Measure how effective emerging new treatments can be
At the moment front-line medical staff are ‘flying blind’, having no option but to risk their lives and the lives of the people they’re caring for. This test is based on animal free research, and it can be in use in a matter of weeks.
The new test will be trialled on human patients with COVID-19 and the results compared with current methods of testing.